文献速递消化道肿瘤与早癌消化内镜

粪便免疫化学与高灵敏度愈创木脂试验在结直肠癌筛查中的比较

A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.
PubMed 文献 · Am J Gastroenterol · 2017-10-10

研究纳入1006例50-75岁无症状计划接受筛查结肠镜检查的患者,比较两种粪便免疫化学试验(InSure FIT和OC FIT-CHEK)与高灵敏度愈创木脂粪便隐血试验Hemoccult II SENSA检测进展期结直肠肿瘤的性能。InSure FIT灵敏度最高为26.3%,其次OC FIT-CHEK为15.1%,Hemoccult II SENSA为7.4%。所有试验特异度较高,介于96.8%至98.6%之间。

要点

  • InSure FIT检测进展期结直肠肿瘤的灵敏度为26.3%,显著高于OC FIT-CHEK的15.1%和Hemoccult II SENSA的7.4%。
  • 三种试验的特异度均较高,介于96.8%至98.6%之间。
  • 作者认为部分FIT比高灵敏度愈创木脂试验更敏感,但需在更大规模无症状人群中确认。

核心结论

  • 作者认为部分粪便免疫化学试验比高灵敏度愈创木脂粪便隐血试验Hemoccult II SENSA更敏感,但需在更大规模无症状人群中确认。
  • 作者认为需要比较本研究所检FIT与其他FIT以确定最佳人群筛查试验。

研究设计与样本

  • 研究纳入1006例50-75岁无症状、计划在明尼阿波利斯和印第安纳波利斯都市区消化内科诊所接受筛查结肠镜检查的患者。
  • 每名参与者被要求在结肠镜检查前完成全部三种粪便试验。
  • 以筛查结肠镜结果为参考标准评估每种试验的性能特征。

主要发现

  • 检测进展期结直肠肿瘤的灵敏度InSure FIT最高为26.3%(95%CI 15.9-40.7),其次OC FIT-CHEK为15.1%(95%CI 6.7-26.1),Hemoccult II SENSA为7.4%(95%CI 1.9-17.0)。
  • InSure FIT灵敏度在统计学上显著高于OC FIT-CHEK,灵敏度绝对差为11.2%(95%CI 0.4-24.2)。
  • InSure FIT灵敏度在统计学上显著高于Hemoccult II SENSA,灵敏度差为18.9%(95%CI 10.2-32.6)。
  • 所有试验的特异度均较高,介于96.8%至98.6%之间。

关键数值与推荐

  • 进展期结直肠肿瘤检测灵敏度:InSure FIT 26.3%(95%CI 15.9-40.7),OC FIT-CHEK 15.1%(95%CI 6.7-26.1),Hemoccult II SENSA 7.4%(95%CI 1.9-17.0)。
  • InSure FIT与OC FIT-CHEK灵敏度绝对差为11.2%(95%CI 0.4-24.2),InSure FIT与Hemoccult II SENSA灵敏度差为18.9%(95%CI 10.2-32.6)。
  • 三种试验特异度介于96.8%至98.6%之间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出这些结果需要在更大规模无症状人群中确认。
  • 作者指出需要比较本研究所检FIT与其他FIT以确定最佳人群筛查试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Annual testing using either a high-sensitivity guaiac fecal occult blood test (HS-gFOBT) or a fecal immunochemical test (FIT) is recommended for screening average-risk people for colorectal cancer. We compared the performance characteristics of the HS-gFOBT Hemoccult II SENSA and two FITs (InSure FIT and OC FIT-CHEK) for detecting advanced colorectal neoplasia. METHODS: The study included 1,006 asymptomatic patients, aged 50-75 years, who were scheduled to receive a screening colonoscopy at gastroenterology practices in the Minneapolis and Indianapolis metropolitan areas. Each participant was asked to complete all three stool tests before their colonoscopy. Each test's performance characteristics were evaluated using the screening colonoscopic results as the reference standard. RESULTS: Sensitivity for detecting advanced colorectal neoplasia was highest for InSure FIT (26.3%, 95% confidence interval (CI) 15.9-40.7), followed by OC FIT-CHEK (15.1%, 95% CI 6.7-26.1) and Hemoccult II SENSA (7.4%, 95% CI 1.9-17.0). InSure FIT was statistically significantly more sensitive than both OC FIT-CHEK (absolute difference in sensitivity=11.2%, 95% CI 0.4-24.2) and Hemoccult II SENSA (difference in sensitivity=18.9%, 95% CI 10.2-32.6). Specificities were relatively high for all tests (between 96.8% and 98.6%). CONCLUSIONS: Our results suggest that some FITs are more sensitive than the HS-gFOBT Hemoccult II SENSA, but these results need to be confirmed in larger asymptomatic populations. Comparisons between the FITs examined in this study and other FITs are needed to determine the best tests for population screening.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shapiro JA, Bobo JK, Church TR, et al. A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening. Am J Gastroenterol. 2017. PMID: 29016558. doi:10.1038/ajg.2017.285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。